Barclays raised the firm’s price target on AbbVie to $200 from $187 and keeps an Overweight rating on the shares. The company reported a strong quarter and raised the 2024 guidance, the analyst tells investors in a research note. The firm says AbbVie’s 2025 growth messaging “incrementally de-risks” the over $12 in earnings per share for 2025.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- ABBV Earnings: AbbVie Exceeds Q2 Expectations Driven by Strong Immunology Sales
- AbbVie Reports Second-Quarter 2024 Financial Results
- Options Volatility and Implied Earnings Moves Today, July 25, 2024
- Notable companies reporting before tomorrow’s open
- Frontier Medicines announces milestone payment in AbbVie partnership